Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myco Pharmaceuticals

Executive Summary

Cambridge, Mass.-based biotech startup names Barry Berkowitz, PhD, as president and CEO; William Timberlake, PhD, to VP-research; and Sean O'Connor, PhD, to director of drug discovery. Berkowitz was the founder and chief exec at the start-up Magainin Pharmaceuticals and served as an exec at SmithKline Beckman. Timberlake, a geneticist, joins from the University of Georgia. O'Connor was formerly with Bristol-Myers Squibb. Myco, which recently raised $4 mil. in venture capital backing, will focus initially on discovering and developing "proprietary anti-fungal and other anti-infective drugs" based on fungal genetics and molecular biology, firm says. The startup expects to have $6 mil. total in initial financing within the year.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel